Compare Amgen, Inc. (AMGN) vs Open Text Corporation (OTEX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Open Text Corporation — how do they compare? Amgen, Inc. trades at $415.07 (market cap $225.15B), while Open Text Corporation trades at $24.89 (market cap $5.80B). The key difference: Amgen, Inc. is far larger — about 38.8× Open Text Corporation's market cap, and Open Text Corporation pays the higher dividend (4.68%). Which is the better fit depends on your goals.
| AMGN | OTEX | |
|---|---|---|
Market Cap | $225.15B | $5.80B |
Sector | Health | Technology |
52-Week High | $417.84 | $39.69 |
52-Week Low | $271.18 | $20.01 |
Enterprise Value | $268.47B | $10.82B |
Dividend Yield | 2.42% | 4.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amgen (AMGN) trades at $417.84, up 0.85% today, near its R1 resistance of $418. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, and revenue exceeding $10 billion. Analyst consensus is bullish with 23 Buy ratings, a $392.53 price target, and technical indicators signaling a bullish trend from moving averages, though RSI levels suggest overbought conditions.
Outlook remains positive driven by robust product growth and raised 2026 guidance, but risks include high debt levels and competitive pressures. The stock offers a dividend yield supported by consistent payouts, with investor sentiment bolstered by recent earnings outperformance and media coverage highlighting growth prospects.
Open Text Corporation (OTEX) trades at $23.95, down 0.13% on the day, with a bearish technical signal from moving averages and oscillators. The stock shows strong fundamentals with a P/E of 9.28, net income margin of 12.26%, and consistent earnings beats in recent quarters. Recent news highlights Q4 2026 results with cloud revenue growth and strategic AI investments.
OTEX presents a value opportunity with low valuation multiples and a 4.7% dividend yield, supported by analyst consensus target of $29.33. Risks include high debt levels and competitive pressures in the software sector. The stock's current price near 52-week lows suggests potential upside if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Open Text Corporation
Open Text Corporation is a global leader in Enterprise Information Management (EIM) software and solutions. The company provides a comprehensive platform that helps organizations manage, secure, and leverage their unstructured digital content, including documents, emails, and media files. OTEX's offerings span content management, business process management, customer experience management, and security, serving large enterprises across various industries worldwide.
Read more on OTEX →
